NASDAQ: BPTSBiophytis Sa Stock
$0.29-0.04 (-12.12%)
Updated Apr 19, 2024
Biophytis shares are trading lower... find out Why BPTS Price Moved with a free WallStreetZen account
Why Price MovedBPTS Price
$0.29
Fair Value Price
-$0.01
Market Cap
$3.02M
52 Week Low
$0.27
52 Week High
$4.22
P/E
-0.09x
P/B
-0.72x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$18.92M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-4.11
Operating Cash Flow
-$14M
Beta
1.23
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BPTS Overview
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BPTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BPTS ($0.29) is overvalued by 5,559.53% relative to our estimate of its Fair Value price of -$0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BPTS ($0.29) is not significantly undervalued (5,559.53%) relative to our estimate of its Fair Value price of -$0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BPTS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BPTS due diligence checks available for Premium users.
Be the first to know about important BPTS news, forecast changes, insider trades & much more!
BPTS News
Valuation
BPTS fair value
Fair Value of BPTS stock based on Discounted Cash Flow (DCF)
Price
$0.29
Fair Value
-$0.01
Undervalued by
5,559.53%
BPTS ($0.29) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BPTS ($0.29) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BPTS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BPTS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.09x
Industry
15.81x
Market
40.51x
BPTS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.72x
Industry
5.74x
BPTS's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BPTS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$13.3M
Liabilities
$17.6M
Debt to equity
-4.11
BPTS's short-term liabilities ($13.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BPTS's short-term assets ($9.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BPTS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BPTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BPTS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BPTS vs Biotech Stocks
Biophytis Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.